1. Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy
   Yong Song et al, 2019, American Journal of Clinical Oncology CrossRef